Caribou Biosciences (CRBU) Competitors $1.98 -0.02 (-0.75%) Closing price 03:59 PM EasternExtended Trading$1.98 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRBU vs. RLMD, AVTE, GYRE, SLDB, and ACRSShould you buy Caribou Biosciences stock or one of its competitors? MarketBeat compares Caribou Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Caribou Biosciences include Relmada Therapeutics (RLMD), Aerovate Therapeutics (AVTE), Gyre Therapeutics (GYRE), Solid Biosciences (SLDB), and Aclaris Therapeutics (ACRS). These companies are all part of the "pharmaceutical products" industry. CRBU vs. RLMDCRBU vs. AVTECRBU vs. GYRECRBU vs. SLDBCRBU vs. ACRSHow does Caribou Biosciences compare to Relmada Therapeutics?Caribou Biosciences (NASDAQ:CRBU) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends. Does the media favor CRBU or RLMD? In the previous week, Caribou Biosciences had 1 more articles in the media than Relmada Therapeutics. MarketBeat recorded 1 mentions for Caribou Biosciences and 0 mentions for Relmada Therapeutics. Caribou Biosciences' average media sentiment score of 0.38 beat Relmada Therapeutics' score of 0.00 indicating that Caribou Biosciences is being referred to more favorably in the media. Company Overall Sentiment Caribou Biosciences Neutral Relmada Therapeutics Neutral Do analysts recommend CRBU or RLMD? Caribou Biosciences currently has a consensus price target of $8.67, indicating a potential upside of 336.61%. Relmada Therapeutics has a consensus price target of $12.00, indicating a potential upside of 65.77%. Given Caribou Biosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Caribou Biosciences is more favorable than Relmada Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Caribou Biosciences 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75Relmada Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71 Do insiders & institutionals have more ownership in CRBU or RLMD? 77.5% of Caribou Biosciences shares are owned by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are owned by institutional investors. 8.5% of Caribou Biosciences shares are owned by company insiders. Comparatively, 14.5% of Relmada Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has higher valuation and earnings, CRBU or RLMD? Relmada Therapeutics has lower revenue, but higher earnings than Caribou Biosciences. Relmada Therapeutics is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCaribou Biosciences$11.16M17.64-$148.12M-$1.42N/ARelmada TherapeuticsN/AN/A-$57.38M-$1.09N/A Which has more volatility and risk, CRBU or RLMD? Caribou Biosciences has a beta of 2.27, indicating that its stock price is 127% more volatile than the broader market. Comparatively, Relmada Therapeutics has a beta of 0.43, indicating that its stock price is 57% less volatile than the broader market. Is CRBU or RLMD more profitable? Relmada Therapeutics has a net margin of 0.00% compared to Caribou Biosciences' net margin of -1,189.14%. Relmada Therapeutics' return on equity of -71.22% beat Caribou Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Caribou Biosciences-1,189.14% -84.17% -60.51% Relmada Therapeutics N/A -71.22%-64.46% SummaryCaribou Biosciences beats Relmada Therapeutics on 9 of the 15 factors compared between the two stocks.How does Caribou Biosciences compare to Aerovate Therapeutics?Caribou Biosciences (NASDAQ:CRBU) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings. Which has better valuation & earnings, CRBU or AVTE? Aerovate Therapeutics has lower revenue, but higher earnings than Caribou Biosciences. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCaribou Biosciences$11.16M17.64-$148.12M-$1.42N/AAerovate TherapeuticsN/AN/A-$75.52M-$1.70N/A Is CRBU or AVTE more profitable? Aerovate Therapeutics has a net margin of 0.00% compared to Caribou Biosciences' net margin of -1,189.14%. Caribou Biosciences' return on equity of -84.17% beat Aerovate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Caribou Biosciences-1,189.14% -84.17% -60.51% Aerovate Therapeutics N/A -90.19%-77.47% Do institutionals & insiders have more ownership in CRBU or AVTE? 77.5% of Caribou Biosciences shares are owned by institutional investors. 8.5% of Caribou Biosciences shares are owned by company insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media favor CRBU or AVTE? In the previous week, Caribou Biosciences had 1 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 1 mentions for Caribou Biosciences and 0 mentions for Aerovate Therapeutics. Caribou Biosciences' average media sentiment score of 0.38 beat Aerovate Therapeutics' score of 0.00 indicating that Caribou Biosciences is being referred to more favorably in the media. Company Overall Sentiment Caribou Biosciences Neutral Aerovate Therapeutics Neutral Do analysts recommend CRBU or AVTE? Caribou Biosciences currently has a consensus price target of $8.67, indicating a potential upside of 336.61%. Given Caribou Biosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Caribou Biosciences is more favorable than Aerovate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Caribou Biosciences 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility & risk, CRBU or AVTE? Caribou Biosciences has a beta of 2.27, indicating that its share price is 127% more volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market. SummaryCaribou Biosciences beats Aerovate Therapeutics on 13 of the 16 factors compared between the two stocks.How does Caribou Biosciences compare to Gyre Therapeutics?Caribou Biosciences (NASDAQ:CRBU) and Gyre Therapeutics (NASDAQ:GYRE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends. Which has higher earnings and valuation, CRBU or GYRE? Gyre Therapeutics has higher revenue and earnings than Caribou Biosciences. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCaribou Biosciences$11.16M17.64-$148.12M-$1.42N/AGyre Therapeutics$116.59M5.13$5.03M-$0.09N/A Do analysts rate CRBU or GYRE? Caribou Biosciences currently has a consensus price target of $8.67, suggesting a potential upside of 336.61%. Gyre Therapeutics has a consensus price target of $17.00, suggesting a potential upside of 175.88%. Given Caribou Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Caribou Biosciences is more favorable than Gyre Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Caribou Biosciences 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75Gyre Therapeutics 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more risk and volatility, CRBU or GYRE? Caribou Biosciences has a beta of 2.27, suggesting that its stock price is 127% more volatile than the broader market. Comparatively, Gyre Therapeutics has a beta of 2.03, suggesting that its stock price is 103% more volatile than the broader market. Do institutionals and insiders hold more shares of CRBU or GYRE? 77.5% of Caribou Biosciences shares are owned by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are owned by institutional investors. 8.5% of Caribou Biosciences shares are owned by company insiders. Comparatively, 10.0% of Gyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is CRBU or GYRE more profitable? Gyre Therapeutics has a net margin of -5.44% compared to Caribou Biosciences' net margin of -1,189.14%. Gyre Therapeutics' return on equity of 3.13% beat Caribou Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Caribou Biosciences-1,189.14% -84.17% -60.51% Gyre Therapeutics -5.44%3.13%2.67% Does the media favor CRBU or GYRE? In the previous week, Gyre Therapeutics had 2 more articles in the media than Caribou Biosciences. MarketBeat recorded 3 mentions for Gyre Therapeutics and 1 mentions for Caribou Biosciences. Caribou Biosciences' average media sentiment score of 0.38 beat Gyre Therapeutics' score of -0.32 indicating that Caribou Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Caribou Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Gyre Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryCaribou Biosciences and Gyre Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.How does Caribou Biosciences compare to Solid Biosciences?Solid Biosciences (NASDAQ:SLDB) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations. Do analysts recommend SLDB or CRBU? Solid Biosciences currently has a consensus price target of $16.36, suggesting a potential upside of 152.21%. Caribou Biosciences has a consensus price target of $8.67, suggesting a potential upside of 336.61%. Given Caribou Biosciences' higher possible upside, analysts plainly believe Caribou Biosciences is more favorable than Solid Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Solid Biosciences 1 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.92Caribou Biosciences 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75 Do insiders & institutionals hold more shares of SLDB or CRBU? 81.5% of Solid Biosciences shares are held by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are held by institutional investors. 1.9% of Solid Biosciences shares are held by company insiders. Comparatively, 8.5% of Caribou Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has higher valuation and earnings, SLDB or CRBU? Caribou Biosciences has higher revenue and earnings than Solid Biosciences. Solid Biosciences is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSolid BiosciencesN/AN/A-$174.32M-$1.95N/ACaribou Biosciences$11.16M17.64-$148.12M-$1.42N/A Which has more volatility and risk, SLDB or CRBU? Solid Biosciences has a beta of 2.47, meaning that its share price is 147% more volatile than the broader market. Comparatively, Caribou Biosciences has a beta of 2.27, meaning that its share price is 127% more volatile than the broader market. Does the media refer more to SLDB or CRBU? In the previous week, Solid Biosciences had 1 more articles in the media than Caribou Biosciences. MarketBeat recorded 2 mentions for Solid Biosciences and 1 mentions for Caribou Biosciences. Caribou Biosciences' average media sentiment score of 0.38 beat Solid Biosciences' score of 0.25 indicating that Caribou Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solid Biosciences 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Caribou Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is SLDB or CRBU more profitable? Solid Biosciences has a net margin of 0.00% compared to Caribou Biosciences' net margin of -1,189.14%. Solid Biosciences' return on equity of -73.42% beat Caribou Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Solid BiosciencesN/A -73.42% -61.13% Caribou Biosciences -1,189.14%-84.17%-60.51% SummaryCaribou Biosciences beats Solid Biosciences on 8 of the 15 factors compared between the two stocks.How does Caribou Biosciences compare to Aclaris Therapeutics?Caribou Biosciences (NASDAQ:CRBU) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment. Is CRBU or ACRS more profitable? Aclaris Therapeutics has a net margin of -832.58% compared to Caribou Biosciences' net margin of -1,189.14%. Aclaris Therapeutics' return on equity of -55.89% beat Caribou Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Caribou Biosciences-1,189.14% -84.17% -60.51% Aclaris Therapeutics -832.58%-55.89%-38.49% Which has more volatility and risk, CRBU or ACRS? Caribou Biosciences has a beta of 2.27, meaning that its share price is 127% more volatile than the broader market. Comparatively, Aclaris Therapeutics has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market. Do insiders and institutionals hold more shares of CRBU or ACRS? 77.5% of Caribou Biosciences shares are held by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are held by institutional investors. 8.5% of Caribou Biosciences shares are held by insiders. Comparatively, 5.6% of Aclaris Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media favor CRBU or ACRS? In the previous week, Aclaris Therapeutics had 1 more articles in the media than Caribou Biosciences. MarketBeat recorded 2 mentions for Aclaris Therapeutics and 1 mentions for Caribou Biosciences. Caribou Biosciences' average media sentiment score of 0.38 beat Aclaris Therapeutics' score of 0.00 indicating that Caribou Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Caribou Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aclaris Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger earnings and valuation, CRBU or ACRS? Aclaris Therapeutics has lower revenue, but higher earnings than Caribou Biosciences. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCaribou Biosciences$11.16M17.64-$148.12M-$1.42N/AAclaris Therapeutics$7.83M80.98-$64.92M-$0.56N/A Do analysts rate CRBU or ACRS? Caribou Biosciences currently has a consensus target price of $8.67, suggesting a potential upside of 336.61%. Aclaris Therapeutics has a consensus target price of $11.29, suggesting a potential upside of 148.58%. Given Caribou Biosciences' higher probable upside, research analysts plainly believe Caribou Biosciences is more favorable than Aclaris Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Caribou Biosciences 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75Aclaris Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.00 SummaryAclaris Therapeutics beats Caribou Biosciences on 11 of the 17 factors compared between the two stocks. Get Caribou Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CRBU and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRBU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRBU vs. The Competition ExportMetricCaribou BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$196.87M$3.36B$6.34B$12.28BDividend YieldN/A2.32%2.80%5.36%P/E Ratio-1.4019.0220.9225.48Price / Sales17.64278.81521.1573.33Price / CashN/A125.3543.1855.00Price / Book1.936.909.987.01Net Income-$148.12M$24.23M$3.55B$335.16M7 Day Performance-7.24%0.65%0.40%-0.30%1 Month Performance-11.78%-0.55%-0.04%1.14%1 Year Performance95.57%63.42%34.95%34.69% Caribou Biosciences Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRBUCaribou Biosciences2.399 of 5 stars$1.99-0.8%$8.67+336.6%+81.8%$196.87M$11.16MN/A100Gap DownRLMDRelmada Therapeutics2.2706 of 5 stars$7.36+0.5%$12.00+63.0%+1,101.0%$767.78MN/AN/A10AVTEAerovate TherapeuticsN/A$25.81+6.6%N/A+194.9%$748.10MN/AN/A20High Trading VolumeGYREGyre Therapeutics2.3194 of 5 stars$7.09-5.1%$17.00+139.8%-47.0%$724.54M$116.59MN/A40SLDBSolid Biosciences2.6461 of 5 stars$7.68+5.6%$16.09+109.5%+119.3%$715.47MN/AN/A100 Related Companies and Tools Related Companies Relmada Therapeutics Competitors Aerovate Therapeutics Competitors Gyre Therapeutics Competitors Solid Biosciences Competitors Aclaris Therapeutics Competitors CryoPort Competitors CytomX Therapeutics Competitors Sutro Biopharma Competitors Zevra Therapeutics Competitors Arvinas Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRBU) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Caribou Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Caribou Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
